These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 33257471)

  • 1. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
    Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
    Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Krüppel-like factor 14 regulates lipid metabolism in nonalcoholic steatohepatitis mice.
    Chen X; Shi W; Xie Y; Wang Y; Yao Q; Ke H; Xu X; Liu H; Liu P; Zhou X
    FASEB J; 2023 Aug; 37(8):e23070. PubMed ID: 37389939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
    Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
    Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
    Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
    Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.
    Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H
    J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis.
    Bechmann LP; Vetter D; Ishida J; Hannivoort RA; Lang UE; Kocabayoglu P; Fiel MI; Muñoz U; Patman GL; Ge F; Yakar S; Li X; Agius L; Lee YM; Zhang W; Hui KY; Televantou D; Schwartz GJ; LeRoith D; Berk PD; Nagai R; Suzuki T; Reeves HL; Friedman SL
    J Hepatol; 2013 May; 58(5):1000-6. PubMed ID: 23353867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
    Cai D; Li Y; Zhang K; Zhou B; Guo F; Holm L; Liu HY
    J Cell Physiol; 2021 Jun; 236(6):4387-4402. PubMed ID: 33184849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
    J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydromyricetin ameliorates hepatic steatosis and insulin resistance via AMPK/PGC-1α and PPARα-mediated autophagy pathway.
    Yang Y; Qiu W; Xiao J; Sun J; Ren X; Jiang L
    J Transl Med; 2024 Mar; 22(1):309. PubMed ID: 38532480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD38 Deficiency Protects Mice from High Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Activating NAD
    Xie L; Wen K; Li Q; Huang CC; Zhao JL; Zhao QH; Xiao YF; Guan XH; Qian YS; Gan L; Wang LF; Deng KY; Xin HB
    Int J Biol Sci; 2021; 17(15):4305-4315. PubMed ID: 34803499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes.
    Du X; Osoro EK; Chen Q; Yan X; Gao D; Wu L; Ren J; Feng L; Wu N; Lu K; Yang X; Zhong B; Han Y; Zhang F; Li D; Lan X; Lu S
    Mol Cell Endocrinol; 2022 Apr; 545():111562. PubMed ID: 35051553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
    Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
    Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
    Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
    Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Lactalbumin Peptide Asp-Gln-Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids-Treated HepG2 Cells and High-Fat Diet-Induced NAFLD Mice by Activating the PPARα Pathway.
    Chen H; Ma Y; Qi X; Tian J; Ma Y; Niu T
    Mol Nutr Food Res; 2023 Aug; 67(16):e2200499. PubMed ID: 37354055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
    Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
    J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
    J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD.
    Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A
    J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6.
    Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J
    Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
    Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
    J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel Alisma orientale extract alleviates non-alcoholic steatohepatitis in mice via modulation of PPARα signaling pathway.
    Xie Y; Jin Y; Wen J; Li G; Huai X; Duan Y; Ni F; Fu J; Li M; Li L; Yan M; Cao L; Xiao W; Yang H; Wang ZZ
    Biomed Pharmacother; 2024 Jul; 176():116908. PubMed ID: 38850668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.